AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

806.248

-3.677-0.45%

Number of Gainers:9

Number of Losers:14

Number of Flat:22

PE:- -

High:816.991

Open:809.925

Low:806.079

Close:809.925

Loading ...

BRIEF-Genetic Technologies Says Binding Term Sheets Executed For Strategic Acquisitions

Proteomics International Laboratories Raises AU$12 Million to Fast-Track Diagnostic Test Launch

MT Newswires Live

Genetic Technologies - Binding Term Sheets Executed for Strategic Acquisitions of Ellerfield Wealth and Walker Capital Private

THOMSON REUTERS

Genetic Technologies Ltd - Consideration for Ellerfield Wealth Acquisition a$7.0 Mln

THOMSON REUTERS

Avita Medical Says Dermal Matrix Shows 'Significantly' Faster Wound Bed Vascularization, Autograft Readiness

MT Newswires Live

Epic adds Keith from Lockton as Mid-Atlantic president

Proteomics Says Clinical Validation Study Shows Blood Test Can Detect Esophageal Cancer With High Accuracy

MT Newswires Live

Mayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%

MT Newswires Live

Three ASX 200 shares Warren Buffett could buy

Mayne Pharma - Position Is Termination Notice Not Effective, Matters in Cosette Additional Notice Will Not Give Rise to Right to Terminate Sid

THOMSON REUTERS

Mayne Pharma - Directors Unanimously Recommend Shareholders Vote in Favour of Scheme

THOMSON REUTERS

Mayne Pharma - Intends to Proceed With the Scheme Meeting Convened for 18 June

THOMSON REUTERS

Mayne Pharma - Pursuing Litigation to Establish Sid Remains Binding Is in Best Interest of Shareholders

THOMSON REUTERS

Mayne Pharma - Has Commenced Proceedings Which Will Determine Whether or Not the Sid Has Been Validly Terminated

THOMSON REUTERS

Immuron Limited Announces New Share Issue with 116,680 Ordinary Fully Paid Securities Quoted

BRIEF-Mayne Pharma Receives Purported Notice To Terminate SID

BUZZ-Australia's Mayne Pharma slides on US co's notice to scrap $432 mln deal

Clinuvel Pharmaceuticals Progresses Vitiligo Treatment Candidate Trial; Shares Jump 8%

MT Newswires Live

ASX Alert-Mayne Pharma Receives Purported Notice to Terminate Sid-Myx.ax

THOMSON REUTERS

Mayne Pharma - Intends to Reject Cosette Termination Notice as Invalid, Reiterates Position That No Mayne Material Adverse Change Triggered

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":806.24774,"timestamp":1749189599976,"preClose":809.925,"halted":0,"volume":49882817,"delay":0,"changeRate":-0.00454,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-3.677246,"latestTime":"06-06 16:00:00 AEST","open":809.925,"high":816.99097,"low":806.07916,"amount":127636809,"amplitude":0.013473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749168000000,1749189600000]],"turnoverRate":0.001585,"increases":8,"decrements":16,"flats":19,"marketCap":126924971440.99219,"floatMarketCap":124496830075.07617},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":816.99097,"amplitude":0.013473,"preClose":809.925,"low":806.07916,"latestPrice":806.24774,"volume":49882817,"delay":0,"open":809.925,"prevYearClose":936.801,"prevWeekClose":825.374,"prevMonthClose":825.374,"prevQuarterClose":815.605,"fiveDayClose":825.374,"twentyDayClose":797.289,"sixtyDayClose":829.898,"secType":"PLATE","market":"AU","turnoverRate":0.001585,"marketCap":126924971440.99219,"floatMarketCap":124496830075.07617,"timestamp":1749189599976,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":9,"down":14,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541855226","title":"BRIEF-Genetic Technologies Says Binding Term Sheets Executed For Strategic Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2541855226","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541855226?lang=en_us&edition=fundamental","pubTime":"2025-06-06 18:00","pubTimestamp":1749204042,"startTime":"0","endTime":"0","summary":"BRIEF-Genetic Technologies Says Binding Term Sheets Executed For Strategic AcquisitionsJune 6 (Reuters) - Genetic Technologies Ltd GTG.AX:BINDING TERM SHEETS EXECUTED FOR STRATEGIC ACQUISITIONS OF ELL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S80SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTG.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2541882936","title":"Proteomics International Laboratories Raises AU$12 Million to Fast-Track Diagnostic Test Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2541882936","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541882936?lang=en_us&edition=fundamental","pubTime":"2025-06-06 12:56","pubTimestamp":1749185803,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  has completed a AU$12 million capital raise, combining a AU$4.5 million institutional and directors placement with an oversubscribed AU$7.5 million share purchase plan , to accelerate the launch of its suite of diagnostic tests, according to a Thursday filing with the Australian bourse.The upsized and heavily oversubscribed SPP enabled eligible shareholders to purchase approximately 20.3 million new shares at AU$0.37 each, with one free option granted for every two shares, the filing said.Proceeds from the capital raise will fast-track the launch of three Promarker tests in both Australia and the US, support system upgrades in Australia, establish lab platforms in the US, advance pipeline tests, including OxiDx, and cover working capital and offer expenses, the filing added.New shares and new options under the SPP are scheduled to be issued on June 6.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FAST","BK4104","XKO.AU","BK4588","BK4567","XAO.AU","PIQ.AU","IE00BFXG0V08.USD","IE00B5TLWC47.USD","XJO.AU","BK7048","BK4585","BK7508","IE00BYQQ9H92.USD"],"gpt_icon":0},{"id":"2541988477","title":"Genetic Technologies - Binding Term Sheets Executed for Strategic Acquisitions of Ellerfield Wealth and Walker Capital Private","url":"https://stock-news.laohu8.com/highlight/detail?id=2541988477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541988477?lang=en_us&edition=fundamental","pubTime":"2025-06-06 12:42","pubTimestamp":1749184974,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S80SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTG.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2541884088","title":"Genetic Technologies Ltd -  Consideration for Ellerfield Wealth Acquisition a$7.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2541884088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541884088?lang=en_us&edition=fundamental","pubTime":"2025-06-06 12:42","pubTimestamp":1749184974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S80SF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","GTG.AU","BK7508"],"gpt_icon":0},{"id":"2541500142","title":"Avita Medical Says Dermal Matrix Shows 'Significantly' Faster Wound Bed Vascularization, Autograft Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2541500142","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541500142?lang=en_us&edition=fundamental","pubTime":"2025-06-06 06:47","pubTimestamp":1749163648,"startTime":"0","endTime":"0","summary":"Avita Medical (ASX:AVH) published clinical results that showed two patients with complex full-thickness hand wounds treated with its collagen-based dermal matrix, Cohealyx, achieved autograft readines","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","AVH.AU"],"gpt_icon":0},{"id":"2541304533","title":"Epic adds Keith from Lockton as Mid-Atlantic president","url":"https://stock-news.laohu8.com/highlight/detail?id=2541304533","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541304533?lang=en_us&edition=fundamental","pubTime":"2025-06-05 14:17","pubTimestamp":1749104275,"startTime":"0","endTime":"0","summary":"Epic adds Keith from Lockton as Mid-Atlantic presidentBy Michael LoneyJune 5 - (The Insurer) - Epic Insurance Brokers & Consultants has appointed Chris Keith as president for the Mid-Atlantic region, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL6N3S710S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","UIS","BK7501","CSL.AU","BK7511","BK7508","BK7067"],"gpt_icon":0},{"id":"2541017328","title":"Proteomics Says Clinical Validation Study Shows Blood Test Can Detect Esophageal Cancer With High Accuracy","url":"https://stock-news.laohu8.com/highlight/detail?id=2541017328","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541017328?lang=en_us&edition=fundamental","pubTime":"2025-06-05 12:02","pubTimestamp":1749096145,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  said it has published study results showing its PromarkerEso blood test can diagnose Esophageal adenocarcinoma , the predominant form of esophageal cancer, with high accuracy, according to a Thursday filing with the Australian bourse.The test showed accurately detected EAC, with over 91% sensitivity and about 99% specificity in a 147-person validation study, the filing said.Shares of the company rose past 1% in recent Thursday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","BK7508","EAC","PIQ.AU"],"gpt_icon":0},{"id":"2541166400","title":"Mayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541166400","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541166400?lang=en_us&edition=fundamental","pubTime":"2025-06-05 09:55","pubTimestamp":1749088522,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group's  board continues to recommend shareholders accept the scheme implementation deed  to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.Shares of the company rose past 3% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4006","BK7096","MYX.AU","SID"],"gpt_icon":0},{"id":"2541101397","title":"Three ASX 200 shares Warren Buffett could buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2541101397","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541101397?lang=en_us&edition=fundamental","pubTime":"2025-06-05 08:49","pubTimestamp":1749084560,"startTime":"0","endTime":"0","summary":"The ASX may be unfamiliar territory for Warren Buffett, the outgoing CEO ofBerkshire Hathaway. But if the Oracle of Omaha turned his eye to the ASX 200, he would use his long-standing investment princ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/06/05/three-asx-200-shares-warren-buffett-could-buy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0742534661.SGD","LU0234570918.USD","IE00BK4W5M84.HKD","CBA.AU","LU0251131958.USD","BK7135","BK4550","BK7508","LU0234572021.USD","BK7501","LU0417517546.SGD","LU0130102774.USD","LU1571399168.USD","IE000M9KFDE8.USD","BK7511","BK4533","LU0149725797.USD","LU0251142724.SGD","BRK.A","LU1280957306.USD","IE00B3S45H60.SGD","IE0034235303.USD","LU0256863811.USD","IE00BKDWB100.SGD","LU1366333091.USD","CSL.AU","LU0154236417.USD","BK7041","LU0787776722.HKD","WES.AU","LU1074936037.SGD","BRK.B","IE00BWXC8680.SGD","LU0971096721.USD","LU2168564222.USD","LU0170899867.USD","BK7153","LU0683600562.USD","BK4176","LU0980610538.SGD","BK7067","BK4585","BK4581","BK4534","LU0053666078.USD","LU2168564149.EUR","LU0648001328.SGD","LU1201861249.SGD","LU1914381329.SGD","IE00BK4W5L77.USD"],"gpt_icon":1},{"id":"2541509294","title":"Mayne Pharma -  Position Is Termination Notice Not Effective, Matters in Cosette Additional Notice Will Not Give Rise to Right to Terminate Sid","url":"https://stock-news.laohu8.com/highlight/detail?id=2541509294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541509294?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:58","pubTimestamp":1749077929,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70Y3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2541092936","title":"Mayne Pharma - Directors Unanimously Recommend Shareholders Vote in Favour of Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092936?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:58","pubTimestamp":1749077929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70Y3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2541092140","title":"Mayne Pharma -  Intends to Proceed With the Scheme Meeting Convened for 18 June","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092140?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:58","pubTimestamp":1749077929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70Y3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2541092123","title":"Mayne Pharma -  Pursuing Litigation to Establish Sid Remains Binding Is in Best Interest of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092123?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:58","pubTimestamp":1749077929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70Y3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2541009219","title":"Mayne Pharma -  Has Commenced Proceedings Which Will Determine Whether or Not the Sid Has Been Validly Terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2541009219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541009219?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:58","pubTimestamp":1749077929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70Y3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2540063294","title":"Immuron Limited Announces New Share Issue with 116,680 Ordinary Fully Paid Securities Quoted","url":"https://stock-news.laohu8.com/highlight/detail?id=2540063294","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540063294?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:00","pubTimestamp":1749038456,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced a new issue of ordinary fully paid shares, with 116,680 securities set to be quoted. This issuance is part of a previously announced transaction, as outlined in an earlier Appendix 3B submission. The new shares are scheduled for issue on June 3, 2025, under the ASX security code IMC. This move by the company aligns with its ongoing strategy to enhance its capital structure and fund its business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDLc8MNFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2540203621","title":"BRIEF-Mayne Pharma Receives Purported Notice To Terminate SID","url":"https://stock-news.laohu8.com/highlight/detail?id=2540203621","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540203621?lang=en_us&edition=fundamental","pubTime":"2025-06-04 14:12","pubTimestamp":1749017528,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Receives Purported Notice To Terminate SIDJune 4  - Mayne Pharma Group Ltd MYX.AX:MAYNE PHARMA RECEIVES PURPORTED NOTICE TO TERMINATE SID-MYX.AXMAYNE PHARMA RECEIVES PURPORTED NOTICE TO TERMINATE SCHEME IMPLEMENTATION DEED FROM COSETTEINTENDS TO REJECT COSETTE TERMINATION NOTICE AS INVALID, REITERATES POSITION THAT NO MAYNE MATERIAL ADVERSE CHANGE TRIGGEREDFurther company coverage: MYX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S60D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2540903376","title":"BUZZ-Australia's Mayne Pharma slides on US co's notice to scrap $432 mln deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2540903376","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540903376?lang=en_us&edition=fundamental","pubTime":"2025-06-04 13:10","pubTimestamp":1749013855,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma slides on US co's notice to scrap $432 mln deal** Mayne Pharma MYX.AX slides as much as 12.5% to A$4.14, lowest since November 21, 2024** Co gets purported notice to terminate $432 million acquisition offer from U.S.-based Cosette Pharmaceuticals** Says it intends to reject termination notice as invalid** Stock set for biggest intraday pct loss since May 21, when MYX posted its worst day in 16 years, plunging 30%, after Cosette initiated a review of its buyout offer** About 3.4 mln shares traded in stock's busiest day since May 21** MYX last down 5.7%, takes YTD losses to ~10%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nL6N3S7092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2540087058","title":"Clinuvel Pharmaceuticals Progresses Vitiligo Treatment Candidate Trial; Shares Jump 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087058?lang=en_us&edition=fundamental","pubTime":"2025-06-04 11:24","pubTimestamp":1749007474,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said the first clinical observations of its CUV105 study of the Scenesse treatment candidate in vitiligo showed repigmentation of vitiliginous lesions on the face, b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2540087791","title":"ASX Alert-Mayne Pharma Receives Purported Notice to Terminate Sid-Myx.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087791?lang=en_us&edition=fundamental","pubTime":"2025-06-04 11:23","pubTimestamp":1749007419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S60D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2540087714","title":"Mayne Pharma -  Intends to Reject Cosette Termination Notice as Invalid, Reiterates Position That No Mayne Material Adverse Change Triggered","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087714?lang=en_us&edition=fundamental","pubTime":"2025-06-04 11:23","pubTimestamp":1749007419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S60D7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":74,"code":"91000000","status":"200"}]}}